Liver Retransplantation in Patients with HIV-1 Infection: An International Multicenter Cohort Study

F. Agüero, A. Rimola, P. Stock, P. Grossi, J. K. Rockstroh, K. Agarwal, C. Garzoni, L. A. Barcan, F. Maltez, C. Manzardo, M. Mari, M. V. Ragni, E. Anadol, F. Di Benedetto, Seigo Nishida, M. Gastaca, Jose M. Miró

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Liver retransplantation is performed in HIV-infected patients, although its outcome is not well known. In an international cohort study (eight countries), 37 (6%; 32 coinfected with hepatitis C virus [HCV] and five with hepatitis B virus [HBV]) of 600 HIV-infected patients who had undergone liver transplant were retransplanted. The main indications for retransplantation were vascular complications (35%), primary graft nonfunction (22%), rejection (19%), and HCV recurrence (13%). Overall, 19 patients (51%) died after retransplantation. Survival at 1, 3, and 5 years was 56%, 51%, and 51%, respectively. Among patients with HCV coinfection, HCV RNA replication status at retransplantation was the only significant prognostic factor. Patients with undetectable versus detectable HCV RNA had a survival probability of 80% versus 39% at 1 year and 80% versus 30% at 3 and 5 years (p = 0.025). Recurrence of hepatitis C was the main cause of death in the latter. Patients with HBV coinfection had survival of 80% at 1, 3, and 5 years after retransplantation. HIV infection was adequately controlled with antiretroviral therapy. In conclusion, liver retransplantation is an acceptable option for HIV-infected patients with HBV or HCV coinfection but undetectable HCV RNA. Retransplantation in patients with HCV replication should be reassessed prospectively in the era of new direct antiviral agents.

Original languageEnglish (US)
Pages (from-to)679-687
Number of pages9
JournalAmerican Journal of Transplantation
Volume16
Issue number2
DOIs
StatePublished - Feb 1 2016

Fingerprint

Hepacivirus
Multicenter Studies
HIV Infections
HIV-1
Cohort Studies
Liver
Coinfection
Hepatitis B virus
HIV
RNA
Virus Replication
Survival
Transplants
Recurrence
Hepatitis C
Antiviral Agents
Blood Vessels
Cause of Death

ASJC Scopus subject areas

  • Transplantation
  • Immunology and Allergy
  • Pharmacology (medical)

Cite this

Liver Retransplantation in Patients with HIV-1 Infection : An International Multicenter Cohort Study. / Agüero, F.; Rimola, A.; Stock, P.; Grossi, P.; Rockstroh, J. K.; Agarwal, K.; Garzoni, C.; Barcan, L. A.; Maltez, F.; Manzardo, C.; Mari, M.; Ragni, M. V.; Anadol, E.; Di Benedetto, F.; Nishida, Seigo; Gastaca, M.; Miró, Jose M.

In: American Journal of Transplantation, Vol. 16, No. 2, 01.02.2016, p. 679-687.

Research output: Contribution to journalArticle

Agüero, F, Rimola, A, Stock, P, Grossi, P, Rockstroh, JK, Agarwal, K, Garzoni, C, Barcan, LA, Maltez, F, Manzardo, C, Mari, M, Ragni, MV, Anadol, E, Di Benedetto, F, Nishida, S, Gastaca, M & Miró, JM 2016, 'Liver Retransplantation in Patients with HIV-1 Infection: An International Multicenter Cohort Study', American Journal of Transplantation, vol. 16, no. 2, pp. 679-687. https://doi.org/10.1111/ajt.13461
Agüero, F. ; Rimola, A. ; Stock, P. ; Grossi, P. ; Rockstroh, J. K. ; Agarwal, K. ; Garzoni, C. ; Barcan, L. A. ; Maltez, F. ; Manzardo, C. ; Mari, M. ; Ragni, M. V. ; Anadol, E. ; Di Benedetto, F. ; Nishida, Seigo ; Gastaca, M. ; Miró, Jose M. / Liver Retransplantation in Patients with HIV-1 Infection : An International Multicenter Cohort Study. In: American Journal of Transplantation. 2016 ; Vol. 16, No. 2. pp. 679-687.
@article{3fb1734f835b4092a719e6c8cc046a36,
title = "Liver Retransplantation in Patients with HIV-1 Infection: An International Multicenter Cohort Study",
abstract = "Liver retransplantation is performed in HIV-infected patients, although its outcome is not well known. In an international cohort study (eight countries), 37 (6{\%}; 32 coinfected with hepatitis C virus [HCV] and five with hepatitis B virus [HBV]) of 600 HIV-infected patients who had undergone liver transplant were retransplanted. The main indications for retransplantation were vascular complications (35{\%}), primary graft nonfunction (22{\%}), rejection (19{\%}), and HCV recurrence (13{\%}). Overall, 19 patients (51{\%}) died after retransplantation. Survival at 1, 3, and 5 years was 56{\%}, 51{\%}, and 51{\%}, respectively. Among patients with HCV coinfection, HCV RNA replication status at retransplantation was the only significant prognostic factor. Patients with undetectable versus detectable HCV RNA had a survival probability of 80{\%} versus 39{\%} at 1 year and 80{\%} versus 30{\%} at 3 and 5 years (p = 0.025). Recurrence of hepatitis C was the main cause of death in the latter. Patients with HBV coinfection had survival of 80{\%} at 1, 3, and 5 years after retransplantation. HIV infection was adequately controlled with antiretroviral therapy. In conclusion, liver retransplantation is an acceptable option for HIV-infected patients with HBV or HCV coinfection but undetectable HCV RNA. Retransplantation in patients with HCV replication should be reassessed prospectively in the era of new direct antiviral agents.",
author = "F. Ag{\"u}ero and A. Rimola and P. Stock and P. Grossi and Rockstroh, {J. K.} and K. Agarwal and C. Garzoni and Barcan, {L. A.} and F. Maltez and C. Manzardo and M. Mari and Ragni, {M. V.} and E. Anadol and {Di Benedetto}, F. and Seigo Nishida and M. Gastaca and Mir{\'o}, {Jose M.}",
year = "2016",
month = "2",
day = "1",
doi = "10.1111/ajt.13461",
language = "English (US)",
volume = "16",
pages = "679--687",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Liver Retransplantation in Patients with HIV-1 Infection

T2 - An International Multicenter Cohort Study

AU - Agüero, F.

AU - Rimola, A.

AU - Stock, P.

AU - Grossi, P.

AU - Rockstroh, J. K.

AU - Agarwal, K.

AU - Garzoni, C.

AU - Barcan, L. A.

AU - Maltez, F.

AU - Manzardo, C.

AU - Mari, M.

AU - Ragni, M. V.

AU - Anadol, E.

AU - Di Benedetto, F.

AU - Nishida, Seigo

AU - Gastaca, M.

AU - Miró, Jose M.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Liver retransplantation is performed in HIV-infected patients, although its outcome is not well known. In an international cohort study (eight countries), 37 (6%; 32 coinfected with hepatitis C virus [HCV] and five with hepatitis B virus [HBV]) of 600 HIV-infected patients who had undergone liver transplant were retransplanted. The main indications for retransplantation were vascular complications (35%), primary graft nonfunction (22%), rejection (19%), and HCV recurrence (13%). Overall, 19 patients (51%) died after retransplantation. Survival at 1, 3, and 5 years was 56%, 51%, and 51%, respectively. Among patients with HCV coinfection, HCV RNA replication status at retransplantation was the only significant prognostic factor. Patients with undetectable versus detectable HCV RNA had a survival probability of 80% versus 39% at 1 year and 80% versus 30% at 3 and 5 years (p = 0.025). Recurrence of hepatitis C was the main cause of death in the latter. Patients with HBV coinfection had survival of 80% at 1, 3, and 5 years after retransplantation. HIV infection was adequately controlled with antiretroviral therapy. In conclusion, liver retransplantation is an acceptable option for HIV-infected patients with HBV or HCV coinfection but undetectable HCV RNA. Retransplantation in patients with HCV replication should be reassessed prospectively in the era of new direct antiviral agents.

AB - Liver retransplantation is performed in HIV-infected patients, although its outcome is not well known. In an international cohort study (eight countries), 37 (6%; 32 coinfected with hepatitis C virus [HCV] and five with hepatitis B virus [HBV]) of 600 HIV-infected patients who had undergone liver transplant were retransplanted. The main indications for retransplantation were vascular complications (35%), primary graft nonfunction (22%), rejection (19%), and HCV recurrence (13%). Overall, 19 patients (51%) died after retransplantation. Survival at 1, 3, and 5 years was 56%, 51%, and 51%, respectively. Among patients with HCV coinfection, HCV RNA replication status at retransplantation was the only significant prognostic factor. Patients with undetectable versus detectable HCV RNA had a survival probability of 80% versus 39% at 1 year and 80% versus 30% at 3 and 5 years (p = 0.025). Recurrence of hepatitis C was the main cause of death in the latter. Patients with HBV coinfection had survival of 80% at 1, 3, and 5 years after retransplantation. HIV infection was adequately controlled with antiretroviral therapy. In conclusion, liver retransplantation is an acceptable option for HIV-infected patients with HBV or HCV coinfection but undetectable HCV RNA. Retransplantation in patients with HCV replication should be reassessed prospectively in the era of new direct antiviral agents.

UR - http://www.scopus.com/inward/record.url?scp=84957956290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957956290&partnerID=8YFLogxK

U2 - 10.1111/ajt.13461

DO - 10.1111/ajt.13461

M3 - Article

C2 - 26415077

AN - SCOPUS:84957956290

VL - 16

SP - 679

EP - 687

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 2

ER -